Treatment advances in psoriatic arthritis.
Treatment of psoriatic arthritis, like the treatment of rheumatoid arthritis, now commonly includes the use of inhibitors of tumor necrosis factor in addition to traditional synthetic disease-modifying antirheumatic drugs. This paper examines the most recent data from therapeutic trials in psoriatic arthritis, with particular emphasis on the effectiveness of the tumor necrosis factor inhibitors. Recent data on potential future therapies is discussed as well, along with data on the mechanisms of current therapies that may have relevance for future treatment approaches.
Ruderman
Eric M
EM
Northwestern University Feinberg School of Medicine, 675 North St. Clair, Suite 14-100, Chicago, IL 60611, USA. e-ruderman@northwestern.edu.
D018501:Antirheumatic Agents / Q000627:therapeutic use*; D015535:Arthritis, Psoriatic / Q000188:drug therapy*; D006801:Humans; D012219:Rheumatology / Q000639:trends; D000079424:Tumor Necrosis Factor Inhibitors
D018501:Antirheumatic Agents; D000079424:Tumor Necrosis Factor Inhibitors